Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21
Open Access
- 10 September 2026
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2283-2294
Abstract
Pneumococcal disease (PD) collectively describes Streptococcus pneumoniae infections at various anatomical sites1,2. Infections of usually sterile sites are classified as invasive pneumococcal dise...Keywords
Funding Information
- Merck & Co., Inc.,
- Merck Sharp & Dohme LLC,
This publication has 37 references indexed in Scilit:
- Public health effects of adult pneumococcal vaccination choice amid increased serotype 4 rates in US subpopulationsPublic Health, 2025
- Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United StatesInfectious Diseases and Therapy, 2024
- Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adultsVaccine, 2023
- Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization programVaccine, 2020
- Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The NetherlandsVaccine, 2016
- Serotype epidemiology of invasive pneumococcal disease in Swiss adults: A nationwide population-based studyVaccine, 2014
- The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in EnglandJournal of Infection, 2012
- Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in SwitzerlandVaccine, 2012
- Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United StatesVaccine, 2010
- The risk of sequelae due to pneumococcal meningitis in high-income countries: A systematic review and meta-analysisJournal of Infection, 2010